Stock Data
$0.02 (0.10%)
Asset Type
Common Stock
Exchange
NASDAQ
Currency
USD
Country
USA
Sector
HEALTHCARE
Industry
DIAGNOSTICS & RESEARCH
Fulgent Genetics Inc is a dynamic company specializing in clinical diagnostic and genetic testing solutions. Based in El Monte, California, and founded in 2011, it offers a wide range of services including molecular diagnostic testing, genetic testing, various pathology laboratory tests, oncology tests, and sequencer services for hereditary cancer, reproductive health, and more. Fulgent Genetics also focuses on therapeutic development, particularly in enhancing cancer treatment through nanoencapsulation and targeted therapy platforms. Its innovative picture genetics platform aids in identifying personal health markers, serving a diverse clientele including insurance companies, hospitals, medical institutions, and individuals.
A disruptive billing system transition torpedoed Fulgent's quarter, with the EPS miss blowing past consensus by 32% as gross margin cratered to 30.1% from 42.1% year-ago. Management yanked full-year guidance to $330M–$340M revenue and flagged a $63M–$67M non-GAAP loss, citing processing delays that compressed collections just as the company was scaling pathology operations through recent acquisitions.
0 Articles
No articles found for Fulgent Genetics.
Our top personal finance-related articles today. Your wallet will thank you later.
